Navigation Links
China Kangtai Cactus Biotech to Launch Patented Cactus-based Low Tar, Low or Zero Nicotine Cigarettes

HARBIN, China, Sept. 1 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus Biotech Inc. (OTC Bulletin Board: CKGT), a vertically integrated grower, developer, manufacturer and marketer of a variety of cactus-based products in China, announced today that the company has successfully completed the trial production of cactus-based cigarettes and plans to launch two products in the forth quarter in 2009: (i) low nicotine and (ii) zero nicotine cigarettes. The new patented cactus cigarettes, under the registered trademark "Shengcao" brand, are expected to increase sales by approximately $220,000 in the fourth quarter.

The low nicotine cigarette is made from cactus, honeysuckle, ginkgo biloba leaves and a small amount of tobacco leaves. This cactus-derived cigarette lowers tar and nicotine content by 70%.

The zero nicotine cigarette is made without any tobacco leaves. It offers taste and enjoyment equivalent to regular cigarettes, but eliminates nicotine. It also greatly reduces harm related to secondhand smoke.

China Kangtai CEO Jinjiang Wang said, "The cactus cigarette market shows huge potential for growth in China. China has about 390 million smokers, accounting for 30% of global smokers. Our revolutionary product can not only capture a significant portion of smokers, but also promote consumer consumption in our other health products such as nutraceuticals, nutritious food, health and energy drinks, beer, wine and liquor. We expect the launch of our cactus health-preserving cigarettes also will improve the brand name and reputation of our company."

China Kangtai was awarded patents for these two cactus cigarettes from China's State Intellectual Property Office in 2008. The patent numbers are 2006100102091 and 2006100102087.

About China Kangtai Cactus Biotech Inc.

China Kangtai Cactus Biotech Inc. is a leading grower, developer, producer, and marketer of cactus-derived products, including nutraceuticals, nutritious food, health and energy drinks, beer, wine and liquor, extracts and powders, and animal feed. China Kangtai controls over 387 acres of plants and maintains an active R&D group that holds 18 product patents and is seeking another 12. China Kangtai's high-quality "green" products are sold throughout China via a distribution network that covers 12 of China's 23 provinces and two of China's four municipalities. More information may be found at or via e-mail:

An investment profile on China Kangtai Cactus Biotech Inc. is available at . For an online investor relations kit, visit . For more investor-related questions, contact Susan Zhou, Hawk Associates, at 305-451-1888, e-mail: To subscribe to future releases via e-mail alert, visit .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Hawk Associates
     Susan Zhou
     Tel:   +1-305-451-1888

SOURCE China Kangtai Cactus Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
2. AOBOs Products Included in Chinas Essential Drug List
3. Forty-two of Simceres Generic Drugs Enter Chinas Essential Drug List
4. China Medical Technologies to Announce Unaudited Financial Results for the Fourth Fiscal Quarter and Fiscal Year ended March 31, 2009 and the First Fiscal Quarter ended June 30, 2009 on September 1, 2009
5. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
6. China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results
7. China Sky One Medical, Inc. Announces Record Second Quarter 2009 Results
8. China Biologic Products Schedules 2009 Second Quarter Earnings Conference Call
9. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
11. China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... year and one of the premier annual events for pharmaceutical manufacturing: 2015 Annual ... November 2015, where ISPE hosted the largest number of attendees in more than ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... 19 novembre  2015.  --> Paris , ... --> DERMALOG, le leader de l,innovation biométrique, a ... fois passeports et empreintes sur la même surface de ... passeports et l,autre pour les empreintes digitales. Désormais, un ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):